Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Oct;109:69–77. doi: 10.1016/j.neuropharm.2016.05.013

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 The Authors

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Fig. 2 — Nigral dopaminergic lesion decreases inhibitory control. A. Rewards obtained in DRL20 in baseline (pre surgery), for the 10 first sessions after surgery (post surgery) and for the 10 last sessions before drug challenge (pre drug) (all impulsivity traits included; 2-way ANOVA); B. DRL performances before surgery, after surgery and before drug treatment according to pre-existing impulsivity trait; C. Efficiency (rewards/responses) in DRL20 before surgery, after surgery and before drug challenge (2-way ANOVA); D. Rewards obtained in FCN16 before surgery, after surgery and before drug challenge (all impulsivity traits included; 2-way ANOVA); E. FCN performances before surgery, after surgery and before drug treatment according to pre-existing impulsivity trait; F. Chain length in FCN16 at the 3 periods (3-way ANOVA). Data represent mean ± SEM. p < 0.05 *from baseline, ¤ from sham, Sham: LI: n = 5, Int: n = 12, HI: n = 4; Lesioned: LI: n = 6, Int: n = 11, HI: n = 6.